The use of antibiotics in the treatment of pediatric varicella patients: real-world evidence from the multi-country MARVEL study in Latin America & Europe
Open Access
- 26 June 2019
- journal article
- research article
- Published by Springer Nature in BMC Public Health
- Vol. 19 (1) , 1-11
Abstract
Varicella is a highly contagious childhood disease. Generally benign, serious complications necessitating antibiotic use may occur. The objective of this study was to characterize the rate, appropriateness and patterns of real-world antibiotic prescribing for management of varicella-associated complications, prior to universal varicella vaccination (UVV) implementation. Pooled, post-hoc analysis of 5 international, multicenter, retrospective chart reviews studies (Argentina, Hungary, Mexico, Peru, Poland). Inpatient and outpatient primary pediatric (1–14 years) varicella cases, diagnosed between 2009 and 2016, were eligible. Outcomes, assessed descriptively, included varicella-associated complications and antibiotic use. Three antibiotic prescribing scenarios were defined based on complication profile in chart: evidence of microbiologically confirmed bacterial infection (Scenario A); insufficient evidence confirming microbiological confirmation (Scenario B); no evidence of microbiological confirmation (Scenario C). Stratification was performed by patient status (inpatient vs. outpatient) and country. Four hundred one outpatients and 386 inpatients were included. Mean (SD) outpatient age was 3.6 (2.8) years; inpatient age was 3.1 (2.8) years. Male gender was predominant. Overall, 12.2% outpatients reported ≥1 infectious complication, 3.7% ≥1 bacterial infection, and 0.5% ≥1 microbiologically confirmed infection; inpatient complication rates were 78.8, 33.2 and 16.6%, respectively. Antibiotics were prescribed to 12.7% of outpatients and 68.9% of inpatients. Among users, β-lactamases (class), and clindamycin (agent), dominated prescriptions. Scenario A was assigned to 3.9% (outpatients) vs 13.2% (inpatients); Scenario B: 2.0% vs. 6.0%; Scenario C: 94.1% vs. 80.8%. High rates of infectious complications and antibiotic use are reported, with low rates of microbiological confirmation suggesting possible antibiotic misuse for management of varicella complications.Keywords
Funding Information
- Merck & Co., Inc. (Not applicable)
This publication has 30 references indexed in Scilit:
- Point prevalence of appropriate antimicrobial therapy in a Dutch university hospitalEuropean Journal of Clinical Microbiology & Infectious Diseases, 2015
- Incidence and Use of Resources for Chickenpox and Herpes Zoster in Latin America and the Caribbean—A Systematic Review and Meta-analysisThe Pediatric Infectious Disease Journal, 2012
- Antibiotic Prescribing in Ambulatory Pediatrics in the United StatesPediatrics, 2011
- Surgical Site Infection PreventionAnnals of Surgery, 2011
- Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccinesInternational Journal of Infectious Diseases, 2010
- Inappropriate antimicrobial use in Turkish pediatric hospitals: A multicenter point prevalence surveyInternational Journal of Infectious Diseases, 2010
- Prescribing patterns and utilization of antimicrobial drugs in a tertiary care teaching hospital of a Caribbean developing countryFundamental & Clinical Pharmacology, 2009
- Antibiotic resistance in Latin America: A cause for alarmVaccine, 2009
- Varicella Vaccination in Japan, South Korea, and EuropeThe Journal of Infectious Diseases, 2008
- VaricellaThe Lancet, 2006